Solutions

This classification focuses on the actual medical agents developed for patient care.

Monoclonal Antibodies (mAbs): Laboratory-made molecules engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system’s attack on cells (often used in oncology).
Vaccines: Preparations that provide active acquired immunity to a particular infectious disease, ranging from traditional inactivated vaccines to modern mRNA and recombinant platforms.
Recombinant Proteins & Enzymes: Proteins produced using genetic engineering (e.g., insulin, growth hormones, and clotting factors) to replace or supplement missing or defective proteins in the body.
Cell & Gene Therapies: Cutting-edge treatments that involve modifying a patient’s own cells (like CAR-T therapy) or introducing genetic material into cells to treat or cure diseases at the root cause.
Biosimilars: Highly similar versions of an already approved biological product (“biologics”) that are brought to market after the original patent expires.
Immunomodulators: Drugs that modify the immune response, used to treat autoimmune diseases and various cancers.

This classification focuses on the business model and the stage of the drug development lifecycle.

Drug Discovery & Research: Focuses on the “R” in R&D, identifying biological targets and screening potential molecules.
Clinical Research Organizations (CROs): Service providers that manage clinical trials on behalf of biopharma companies to ensure regulatory compliance and data integrity.
Contract Development & Manufacturing Organizations (CDMOs): Companies that specialize in scaling up production and manufacturing complex biological drugs for other biopharma firms.
Bioinformatics: Firms that leverage data science, AI, and computing power to analyze biological data (genomics, proteomics) to accelerate the discovery process.
Regulatory & Compliance Services: Specialized consulting firms that navigate the complex FDA, EMA, or other national health authority approval processes.

Biopharma technology is increasingly applied to areas outside of human medicine, often grouped into color-coded sub-sectors:

Segment	Primary Focus
Red Biotech	Human medicine and pharmaceutical drug development.
Green Biotech	Agricultural biotechnology (e.g., modified seeds, crop protection).
White Biotech	Industrial biotechnology (e.g., enzymes for manufacturing, biofuels, bio-materials).
Blue Biotech	Marine and aquatic biotechnology (e.g., using marine organisms for drug discovery).

Biopharma vs. Traditional Pharma: The fundamental difference is the origin of the product. Traditional pharma uses chemical synthesis (lab-made chemicals), while biopharma uses biological systems (living cells).
The “Pipeline” Ecosystem: Many small, innovative biopharma startups focus purely on the Drug Discovery phase. Once they hit a proof-of-concept, they are often acquired by larger, integrated firms that have the infrastructure for massive Clinical Trials and Commercial Manufacturing.